Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SeaStar Medical Holding ( (ICU) ) has issued an announcement.
SeaStar Medical announced the FDA approval of its QUELIMMUNE device for pediatric acute kidney injury, marking a significant milestone in its commercialization strategy. The company is currently enrolling patients in a pivotal trial for adult acute kidney injury, a market significantly larger than the pediatric segment. This progress underscores SeaStar’s potential to capture a substantial share of the multibillion-dollar market for inflammation-driven diseases, leveraging its proven SCD platform technology.
More about SeaStar Medical Holding
SeaStar Medical Holding operates within the medical technology industry, providing organ-restoring solutions to critically ill patients through its patented Selective Cytopheretic Device (SCD) platform. The company focuses on addressing life-threatening hyperinflammation and is engaged in developing therapeutic devices for acute kidney injury and other inflammation-driven diseases. With FDA approval for pediatric acute kidney injury and ongoing pivotal trials for adult acute kidney injury, SeaStar Medical is positioned to expand its market presence.
YTD Price Performance: 2.05%
Average Trading Volume: 230,913
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.88M
See more data about ICU stock on TipRanks’ Stock Analysis page.
